GlaxoSmithKline Pharmaceuticals Limited — Updates, 01-08-2025: Press Release

GSK India reported flat growth for Q1, but maintained sustained profitability. Revenue from Operations stood at INR 805 Cr, with PAT at INR 205 Cr. Despite seasonal disruptions impacting general medicines, key brands gained market share. The vaccines business showed strong momentum, especially adult vaccines with Shingrix. Looking ahead, GSK is set to launch its innovative oncology portfolio, including Jemperli and Zejula, addressing critical unmet needs in cancer treatment and signaling future growth drivers. This strategic investment highlights GSK's commitment to expanding its therapeutic reach.